PREVENTION OF ACUTE MYOCARDIAL DAMAGE BY LOADING DOSES OF STATINS IN ELECTIVE PERCUTANEOUS CORONARY INTERVENTIONS

The open, prospective, randomized comparative study included 68 patients who underwent successful elective endovascular intervention for atherosclerosis-related coronary artery stenosis. At baseline, all patients were taking statins as the standard lipid-lowering therapy long-term. Group 1 included 33 patients who received a loading dose of atorvastatin 80 mg 12 hours before the intervention and the same dose for 2 days with consequent reduction to the standard dose. Average total dose per patient was 320 (260-400) mg for 7 days of hospital stay. Group 2 included 35 patients treated with rosuvastatin 40 mg/day or 260 (240-280) mg for 7 days of hospital stay. The levels of cardiac biomarkers TnI and CK MB were determined at baseline, 12, 24, 48, and 72 hours after PCI. The study demonstrated that the use of high loading doses of potent statins (atorvastatin and rosuvastatin) with planned endovascular interventions on the coronary arteries had a similar impact on the dynamics of cardiac bio-markers during 72 hours after PCI. The use of a loading dose of rosuvastatin had an advantage due to significantly smaller increases in CK MB and TnI (26.7% and 27.1%, respectively) during the first 12 hours after the procedure, 24.3%-decrease in the number of patients with more than 1 x ULN TnI level, and due to 12.1%-decrease in the number of patients with increased CPK MB more than 3 x ULN after the procedure. These observations suggest less acute myocardial damage during the intervention in patients receiving a loading dose of rosuvastatin compared with those receiving a loading dose of atorvastatin.

ишемическая болезнь сердца, стабильная стенокардия, чрескожные коронарные вмешательства, статины, coronary artery disease, stable angina, percutaneous coronary intervention, statins

1. Califf R.M., Abdelmeguid A.E., Kunitz R.E. et al. Myonecrosis after revascularization procedures // J. Am. Coll. Cardiol. - 1998. - Vol. 31. - P. 241-251.

2. Klein R.W., Kramer B.L., Howard E., Lesch M. Incidence and clinical significance of transient creatine kinase elevations and the diagnosis of non-Q wave myocardial infarction associated with coronary angioplasty // J. Am. Coll. Cardiol. - 1991. - Vol. 17. - P. 321-326.

3. Prasad A., Herrmann J. Myocardial Infarction due to percutaneous coronary intervention // N. Eng. J. Med. - 2011. - Vol. 364. - P. 453-464.

4. Ellis S.G., Chew D., Chan A. et al. Death following creatine kinase-MB elevation after coronary intervention. Identification of an early risk period: importance of creatine kinase-MB level, completeness of revascularization, ventricular function and and probable benefit of statin therapy // Circulation. - 2002. - Vol. 106. - P. 1205-1211.

5. Ioannidis J.P.A., Karvouni E., Katritis D.G. Mortality risk conferred by small elevations of creatine-kinase MB isoenzyme after percutaneous intervention // J. Am. Coll. Cardiol. - 2003. - Vol. 42. - P. 1406-1411.

6. Merla R., Reddy N.K., Wang F.W. et al. Meta-analysis of published reports on the effect of statin treatment before percutaneous coronary intervention on periprocedural myonecrosis // Am. J. Cardiol. - 2007. - Vol. 100. - P. 770-776.

7. Veselka J., Prochazkova S., Duchnova R. et al. Pre-procedural statin therapy reduces the risk and extent of cardiac biomarkers release following percutaneous coronary intervention // Heart Vessels. - 2006. - Vol. 21. - P. 146-151.

8. Jones S.P., Trocha S.D., Lefer D.J. Pretreatment with simvastatin attenuates myocardial dysfunction after ischemia and chronic reperfusion // Arterioscler. Thromb. Vasc. Biol. - 2001. - Vol. 21. - P. 2059-2064.

9. Bell R.M., Yellon D.M. Atorvastatin, administered at the onset of reperfusion, and independent of lipid lowering, protects the myocardium by up-regulating a pro-survival pathway // J. Am. Coll. Cardiol. - 2003. - Vol. 41. - P. 508-515.

10. Mensah K., Mocanu M.M., Yellon D.M. Failure to protect the myocardium against ischemia/reperfusion injury after chronic atorvastatin treatment is recaptured by acute atorvastatin treatment: a potential role for phosphatase and tensin homolog deleted on chromosome ten? // J. Am. Coll. Cardiol. - 2005. - No. 45. - Р. 1287-1291.

11. Wang T., Yang Y.J., Xu B. Atorvastatin pretreatment before PCI accelerates both neointimal coverage and reendothelialization after sirolimus-eluting stent implantation using a porcine model: new findings from optical coherence tomography and pathology // J. Am. Coll. Cardiol. - 2012. - Vol. 59. - P. 1196-1209.

12. ВНОК. Диагностика и лечение стабильной стенокардии. Российские рекомендации (второй пересмотр) // Кардиоваскулярная терапия и профилактика. - 2008. - №7(6), приложение 4. - С. 1-28.

13. Показания к реваскуляризации миокарда (Российский cогласительный документ). - М. : НЦССХ им. А. Н. Бакулева РАМН, 2011. - 162 с.

14. Davignon J. Beneficial cardiovascular pleiotropic effects of statins // Circulation. - 2004. - Vol. 109, No. 23, suppl. 1(III). - P. 39-43.

15. Sanguigni V., Pignatelli P., Lenti L. et al. Short-term treatment with atorvastatin reduces platelet CD40 ligand and thrombin generation in hypercholesterolemic patients // Circulation. - 2005. - Vol. 111. - P. 412-419.

16. Hinoi T., Matsuo S., Tadehara F. et al. Acute effect of atorvastatin on coronary circulation measured by transthoracic Doppler echocardiography in patients without coronary artery disease by angiography // Am. J. Cardiol. - 2005. - Vol. 96. - P. 89-91.

17. Pasceri V., Patti G., Nusca A. et al. ARMYDA Investigators. Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: results from the ARMYDA (Atorvastatin for Reduction of Myocardial Damage during Angioplasty) study // Circulation. - 2004. - Vol. 110. - P. 674-678.

18. Briguori C., Colombo A., Airoldi F. et al. Statin administration before percutaneous coronary intervention: impact on periprocedural myocardial infarction // Eur. Heart J. - 2004. - No. 25. - Р. 1822-1828.

19. Briguori C., Visconti G., Focaccio A. et al. Novel Approaches for Preventing or Limiting Events (NAPLES II) Trial // J. Am. Coll. Cardiol. - 2009. - No. 54. - Р. 2157-2163.

20. Sardella G., Conti G., Donahue M. et al. Rosuvastatin pretreatment in patients undergoing elective PCI to reduce the incidence of myocardial periprocedural necrosis: the ROMA trial // Catheter Cardiovasc. Interv. - 2013. - No. 81. - Р. 36-43.

21. Patti G., Cannon C.P., Murphy S.A. et al. Clinical benefit of statin pretreatment in patients undergoing percutaneous coronary intervention. A collaborative patient-level meta-analysis of 13 randomized study // Circulation. - 2011. - Vol. 123. - Р. 1622-1632.

22. Di Sciascio G., Patti G., Pasceri V. et al. Efficacy of atorvastatin reload in patients on chronic statin therapy undergoing percutaneous coronary intervention: results of the ARMYDA-RECAPTURE (Atorvastatin for Reduction of Myocardial Damage During Angioplasty) Randomized Trial // J. Am. Coll. Cardiol. - 2009. - No. 54. - Р. 558-565.

23. Sardella G., Lucisano L., Mancone M. et al. Comparison of high reloading ROsuvastatin and Atorvastatin pretreatment in patients undergoing elective PCI to reduce the incidence of MyocArdial periprocedural necrosis. The ROMA II trial // Int. J. Cardiol. - 2013. - URL: http://dx.doi.org/10.1016/j. ijcard.2013.06.017 (дата обращения 05.04.2015).

24. Zemanek D., Branny M., Martinkovicova L. et al. Effect of seven-day atorvastatin pretreatment on the incidence of periprocedural myocardial infarction following percutaneous coronary intervention in patients receiving long-term statin therapy. A randomized study // Int. J. Cardiol. - 2013. - Vol. 168. - P. 2494-2497.

25. Thygesen К., Alpert J.S., Harvey D. White on behalf of the Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction. Universal definition of myocardial infarction // Eur. Heart J. - 2007. - Vol. 2. - P. 2525-2538.

26. Lim C., van Gaal W.J., Testa L. et al. With the “Universal Definition” measurement of creatine kinase-myocardial band rather than troponin allows more accurate diagnosis of periprocedural necrosis and infarction after coronary intervention // J. Am. Coll. Cardiol. - 2011. - Vol. 57. - P. 653-661.

27. Thygesen K., Alpert J.S., Jaffe A.S. et al. ESC/ACCF/AHA/WHF Task Force for the Universal Definition of Myocardial Infarction. Third universal definition of myocardial infarction // Eur. Heart J. - 2012. - Vol. 33. - P. 2551-2567.